In a previous meta-analysis evaluating the effect of GLP-1 RAs in individuals with obesity without T2D, weekly administration of subcutaneous semaglutide led to a 12.4 kg reduction in body weight, whereas liraglutide, another GLP-1 RA, resulted in a 5.3 kg weight reduction (30). Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.